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ABSTRACT
 Objective: To investigate possible causes of an exces-
sive response to tolvaptan in a woman with syndrome of 
inappropriate antidiuretic hormone secretion (SIADH).
 Methods: A 32-year-old woman was admitted to our 
cardiologic unit 3 months after delivery for hypertension 
and severe hyponatremia (120 mEq/L). Two hyponatremic 
episodes had already been documented in her medical 
history. SIADH was diagnosed and treatment with tolvap-
tan, an arginine vasopressin (AVP) antagonist, was insti-
tuted. After the first 15-mg dose, excessive polyuria (1 L/
hour) and a rapid increase in serum sodium (13 mEq/L in 8 
hours) occurred, so that therapy was stopped and restarted 
2 days later at a reduced dose (5 mg). This level was effec-
tive and well tolerated. To explore the possible pharma-
cokinetic and pharmacodynamic mechanisms underlying 
the patient’s hyperresponsiveness, the following tests were 
carried out: (1) in vivo phenotyping of CYP3A4 activity, 
the cytochrome responsible for tolvaptan metabolism, with 
two probe drugs (omeprazole and dextromethorphan); and 
(2) search for mutations in genes involved in AVP signal-
ing (AVP, V2R, AQP2, OXT).
 Results: Neither phenotyping nor genotyping tests 
evidenced abnormalities capable of explaining the patient’s 
enhanced response to tolvaptan, in that: (1) CYP3A4 activ-
ity was normal-to-high; and (2) genes coding for AVP, 
vasopressin-2 receptor, aquaporin-2, and oxytocin did not 
show any mutations.
 Conclusion: This study excluded many, but not all, 
possible causes of hyperresponsiveness to tolvaptan. Two 
hypotheses concerning pretreatment AVP levels in SIADH 
patients are suggested to address future research. (AACE 
Clinical Case Rep. 2017;3:e357-e360)
Abbreviations:
3MM = 3-methoxy-morphinan; AQP2 = aquaporin-2 
water channel; AVP = arginine vasopressin; CYP3A4 
= cytochrome P450 CYP3A4; DMT = dextrometho-
rphan; OME = omeprazole; OXT = oxytocin; SIADH 
= syndrome of inappropriate antidiuretic hormone 
secretion; SUL = omeprazole sulfone; V2R = vasopres-
sin type 2 receptor
INTRODUCTION
 The syndrome of inappropriate antidiuretic hormone 
secretion (SIADH) is one of the most frequent causes 
of euvolemic hyponatremia (1). Conventional therapy, 
including fluid restriction and diuretics, are generally 
not tolerated well by patients. SALT-1 and SALT-2 trials 
(2) demonstrated that tolvaptan, a vasopressin receptor 2 
antagonist, is a safe and effective alternative, provided that 
careful dose titration is applied. There is a serious risk of 
an excessively rapid increase in sodium serum concentra-
tions resulting in osmotic demyelination, which may cause 
severe neurologic damage.
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CASE REPORT
 A 32-year-old woman was admitted to our cardiologic 
unit for severe hyponatremia, presumed to be due to post-
partum cardiomyopathy. Pregnancy had also been compli-
cated by intra-uterine growth retardation (at the second 
trimester) and pre-eclampsia (at gestational week [GW] 
34) associated with moderate hypertension (140/100 mm 
Hg), which was promptly treated with alpha-methyldopa 
250 mg three times a day and nifedipine 10 mg three times 
a day. Delivery was induced with oxytocin at GW 37. As 
the birth date approached, marked fluid retention (positive 
water balance of 1,000 mL/day) was observed, together 
with slight hyponatremia (131 mEq/L) and chloremia at 
the lower normal limit (98 mEq/L). After the patient had 
been discharged, antihypertensive therapy was gradually 
suspended over a period of 2 months. No other pharmaco-
logic treatments (including contraceptives) were instituted. 
Three months after delivery, she experienced weakness, 
numbness, headache, and pain at neck and knees, associat-
ed with severe hypertension (170/120 mm Hg) and severe 
hyponatremia (117 mEq/L) and was admitted to our unit 
for cardiologic evaluation. Of note, during two previous 
hospital admissions, hyponatremia had already been docu-
mented but overlooked by clinicians; the first, 14 years 
previously, was due to transient onset of scotomas (sodium 
= 132 mEq/L, chloride = 99 mEq/L, uric acid = 0.9 mg/dL) 
and the second, 10 years previously, for acute abdominal 
pain, without objective abdominal and gynecologic find-
ings, which resolved spontaneously (sodium = 118 mEq/L, 
chloride = 87 mEq/L).
 On admission, postpartum cardiomyopathy was 
excluded by ecocardiographic examination, which 
revealed normal heart volume and contractility (ejection 
fraction, 75%). The patient showed no clinical signs of 
fluid retention, despite laboratory signs of hemodilution, 
such as severe hyponatremia (120 mEq/L), hypochlore-
mia (87 mEq/L), and hypouricemia (0.09 mEq/L). Plasma 
osmolality was low (233 mOsm/kg) and natriuria/24 hours 
elevated (299 mEq/24 hours). Urine osmolality was moder-
ately high (488 mOsm/kg) in relation to serum osmolal-
ity but definitely higher than the cutoff of 100 mOsm/
kg used to diagnose SIADH (1). A hydration test with 
isotonic saline (NaCl 0.9%) aggravated the hyponatremia 
(116 mEq/L) and induced typical signs of water retention 
(nausea, vomiting, fatigue, headache). Secondary causes of 
euvolemic hypo-osmolality—such as the use of diuretics, 
hypothyroidism, hypocortisolism, Sheehan syndrome, and 
renal insufficiency—were excluded by specific laboratory 
tests (thyroid-stimulating hormone, 2.26 mU/L; adrenocor-
ticotropic hormone, 14 ng/mL; luteinizing hormone, 1.2 
U/L; follicle-stimulating hormone, 4.9 U/L; prolactin, 17.3 
µg/L; creatinine, 49 µmol/L; Chronic Kidney Disease–
Epidemiology Collaboration creatinine clearance 123 mL/
min), and a diagnosis of idiopathic SIADH (1) was made. 
Accordingly, therapy based on water restriction, oral NaCl 
supplements, and furosemide was instituted. This strategy 
led to gradual restoration of adequate sodium serum levels 
but was poorly tolerated by the patient (nausea, diarrhea, 
intolerance to water restriction). Specific therapy with an 
arginine vasopressin (AVP) receptor inhibitor (tolvaptan) 
was started, at the lowest recommended dose (15 mg/day). 
After administration of the first dose, the patient suffered 
a disproportionate pharmacologic effect, with considerable 
polyuria (1 L/hour) and a rapid increase in serum sodium 
(13 mEq/L in 8 hours), which was effectively controlled by 
abundant hydration with a 5% dextrose solution. Tolvaptan 
therapy was suspended and restarted 2 days later at a 
reduced dose of 5 mg. At the moment of writing, this dose 
still adequately maintains optimal levels of natremia, with-
out dangerous side effects. Figure 1 shows the time course 
of sodium serum concentrations in relation to the various 
diagnostic and therapeutic interventions, and Figure 2 
shows parallel changes in daily diuresis.
 In an attempt to clarify the causes of such unusual 
hypersensitivity, further analyses were carried out to inves-
tigate possible pharmacokinetic or pharmacodynamic 
abnormalities. Since tolvaptan is primarily eliminated 
by cytochrome P450 CYP3A4 (CYP3A4) (3), CYP3A4 
activity was phenotyped, with dextromethorphan (DMT) 
and omeprazole (OME) as probe drugs. After oral admin-
istration of 15 mg DMT and 20 mg OME, concentrations 
of 3-methoxy-morphinan (3MM) in 8-hour postdose urine 
and of OME sulfone (SUL) in 3-hour postdose plasma 
were determined by high-performance liquid chromatogra-
phy methods (4,5), and the corresponding metabolic ratios 
were calculated: log(DMT/3MM) and log(OME/SUL). 
Methodologic details can be found in the cited papers. 
Quantification limits were 10 ng/mL for DMT and 3MM 
and 6 ng/mL for OME and SUL.
 CYP3A4 metabolic activity, as expressed by both 
metabolic ratios, was higher than the mean reported in 
healthy populations (4,5) (Fig. 3), thus excluding impaired 
tolvaptan elimination as a pharmacokinetic cause of hyper-
sensitivity. Possible causes of pharmacodynamic variabil-
ity were also explored later, with particular reference to 
the mechanisms involved in AVP signaling. To explore the 
possibility that the patient’s enhanced response to tolvap-
tan was due to mutations of genes coding for AVP, vaso-
pressin type 2 receptor (V2R), aquaporin-2 water channel 
(AQP2), and oxytocin (OXT), a Sanger sequencing analy-
sis was carried out (6). However, genetic analyses proved 
that all candidate genes were wild type, thus leaving clini-
cal observations unexplained.
DISCUSSION
 Our patient fulfilled all major diagnostic criteria for 
SIADH (1), in particular: (1) serum osmolality was <275 
mOsm/kg; (2) she was clinically euvolemic; (3) urine 
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osmolality was >100 mOsm/kg; (4) no laboratory data 
evidenced adrenal, thyroid, pituitary, or renal insufficien-
cy; and (5) no drugs were administered (e.g., diuretics). 
Also, three supplemental criteria were verified: (1) hypou-
ricemia; (2) failure to correct hyponatremia after 0.9% 
saline infusion; and (3) correction of hyponatremia through 
fluid restriction. Initial therapy based on fluid restriction 
was effective in restoring normal sodium serum levels, but 
the patient developed nausea and diarrhea, probably due 
to oral NaCl supplements. Therefore, she was shifted to 
tolvaptan, an AVP receptor inhibitor, at the standard 15-mg 
dose, which, however, produced an unusually marked 
diuretic effect.
 The ability of tolvaptan to increase sodium serum 
concentrations is quite variable among patients with 
SIADH, so that those who do not meet the target sodium 
concentration of 135 mEq/L after the starting dose of 15 
mg/day can be treated with 30 mg or 60 mg daily, as neces-
sary. Gradual dose titration is recommended, since a too 
rapid correction of hyponatremia (e.g., >12 mEq/L/24 
hours) may result in osmotic demyelination and life-threat-
ening neurologic manifestations. Our patient exhibited 
severe hyponatremia on admission (120 mEq/L); after a 
single 15-mg dose of tolvaptan, sodium concentrations 
increased by 13 mEq/L in 8 hours, but thanks to the prompt 
institution of hydration therapy, she did not develop neuro-
logic symptoms. To our knowledge, only one similar case 
has been reported in the literature, regarding a 51-year-old 
woman who showed a rapid increase in urine output and 
symptomatic hypotension after a 15-mg dose of tolvaptan 
and was then effectively and safely treated with a reduced 
dose of 4.5 mg (7).
 In the SALT-1 and SALT-2 trials, 4 of the 223 patients 
(1.8%) exceeded the desirable rate of sodium correction 
(>0.5 mEq/L/hour) during the first 24 hours of the study. 
It is therefore evident that a subgroup of patients with 
SIADH may be hyperresponsive to tolvaptan, for reasons 
not yet clarified.
 To investigate the causes of the enhanced response 
in our patient, we explored the pharmacokinetic and/
or pharmacodynamic mechanisms which might have 
been involved. First, we measured the in vivo activity of 
CYP3A4, responsible for tolvaptan metabolism, with two 
probe drugs, OME and DMT. Both indicated that CYP3A4 
activity was higher than the mean reported in healthy 
subjects, thus excluding a pharmacokinetic cause of hyper-
responsiveness.
 We then looked for mutations of macromolecules 
possibly involved in the tolvaptan effect. AVP increases 
water permeability along the collecting duct by binding 
the V2 receptor which, in turn, triggers short-term upregu-
lation of the AQP2 water channel and long-term AQP2 
protein transcription. In addition, the role of OXT in induc-
ing SIADH was suggested by two (now dated) reports of 
water intoxication following OXT infusion (8,9) and by 
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Fig. 1. Time-course of sodium plasma concentrations in relation to diag-
nostic and therapeutic interventions. (A) Hydration test with 0.9% saline. 
(B) Water restriction plus oral NaCl plus furosemide. (C) Hydration with 
5% dextrose after a 15-mg tolvaptan dose, which produced abundant 
diuresis. (D) Free hydration plus 5 mg tolvaptan every day.
Fig. 2. Time course of diuresis. Timing of therapeutic interventions are 
indicated by arrows. q.d. = every day.
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Fig. 3. Cytochrome P450 CYP3A4 activity measured with omeprazole 
(OME) and dextromethorphan (DMT) as probe drugs. Corresponding 
metabolic ratios expressed as log ratios between drug and metabolite 
concentrations in plasma or urine, as required (see text). Upper and lower 
segments: normal log(OME/SULF) and log(DMT/3MM) ranges. Mean 
normal values indicated by ×; arrows indicate metabolic ratios determined 
in our patient. 3MM = 3-methoxy-morphinan; SULF = omeprazole sulfone.
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a more recent experimental study (10) that demonstrated 
that OXT can bind the V2 receptor and stimulate water 
permeability of the collecting duct and that its effect can 
be blocked by a V2 receptor inhibitor. However, neither 
agonists of V2R (AVP and OXT) nor the molecules 
involved in signal transduction (V2R and AQP2) revealed 
any genetic abnormalities.
 In principle, the response to an antagonist depends on 
a number of factors, such as relative concentrations of the 
agonist (i.e., AVP) and antagonist (i.e., tolvaptan), number 
and affinity of receptors (i.e., V2R), and changes in postre-
ceptor mechanisms (i.e., AQP2). The results in our patient 
tend to exclude excessive exposure to tolvaptan (CYP3A4 
activity), changes in molecular structures of V2R or AVP/
OXT (no gene mutations) and in signal transduction (no 
AQP2 mutations). Accordingly, hyperresponsiveness to 
tolvaptan may be due to lower plasma AVP concentra-
tions or decreased V2 receptor number. Indeed, Vaghasiya 
et al (11) reported an inverse correlation between baseline 
AVP levels and natremic response to tolvaptan in SIADH 
patients, suggesting that a more complete V2R blockade 
occurs when AVP levels are low.
 Another possibility is that prolonged exposure to 
AVP plasma concentrations may have downregulated the 
patient’s V2 receptors by a ligand-induced internalization 
mechanism. This adaptive mechanism has been demon-
strated in rats (12,13) and is considered responsible for the 
progressive loss of antidiuretic effect of AVP observed in 
humans during prolonged AVP infusion (the “renal escape 
from antidiuresis” phenomenon) (14). According to the 
occupancy receptor theory, a reduced number of receptors 
increases the effect of an antagonist. Both these hypotheses 
foresee an increased V2 receptor occupancy by tolvaptan 
but with opposite mechanisms, one implying relatively low 
and the other relatively high AVP plasma levels.
 We did not measure the AVP plasma levels in our 
patient because the AVP concentration is not a criterion for 
diagnosing SIADH and the AVP assay has methodologic 
limitations (15). However, since a direct correlation has 
been demonstrated between urine osmolality and AVP plas-
ma levels (16), our finding of a moderate increase in urine 
osmolality (488 mOsm/kg) may have reflected a moderate 
increase in AVP plasma levels and a greater susceptibility 
to V2R block.
CONCLUSION
 A few SIADH patients may exhibit an unusually 
intense response to tolvaptan and require doses much lower 
than the lowest recommended (15 mg). Although we could 
not positively identify the cause of hyperresponsiveness in 
our patient, we did exclude some important pharmacoki-
netic and pharmacodynamic mechanisms. Further experi-
mental work is needed to clarify the relationship between 
baseline AVP levels in SIADH patients and response to 
AVP antagonists.
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